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Undoubtedly, timely and appropriate use of renal replacement therapy (RRT) has saved the 
lives of many who without such treatment would have succumbed to the consequences of 
acute kidney injury (AKI).  Technological progress together with increased emphasis on 
multi-organ support has led, in many centres, to implementation of RRT in anticipation of 
absolute indications being proposed.   However, this enthusiasm for “early” treatment has 
been tempered by investigators critical of this approach who advocate a “less is more” 
strategy highlighting both costs and the potential adverse effects of inappropriate therapy. 
Support for this approach is provided by the results of two French randomized controlled 
trials (AKIKI [1] and IDEAL ICU [2]) which both failed to demonstrate any benefit from earlier 
implementation  of RRT compared to a “delayed” strategy for AKI. Indeed, many patients in 
the “delayed” group eventually did not receive RRT. Early initiation of RRT in both studies 
was based on AKI criteria (change in serum creatinine or duration of urine output) in patients 
with multiple organ failure, and it is no surprise that patients randomized in the more 
restrictive arm needed less RRT.  Potential side effects of unwarranted RRT were further 
underlined in the AKIKI trial, with a higher incidence of catheter related infections in the 
“early” group.   The lack of benefit in these studies has promoted the view that RRT may be 
harmful and should be employed only in the face of imminently life-threatening 
consequences of severe renal dysfunction.  While we fully agree that applying an invasive 
therapy when not required is highly undesirable, we feel that the suggestion that RRT is 
intrinsically harmful and to be avoided at all costs is overly nihilistic and neglects the 
important role that RRT may place in the integrated management of the patient with multi-
organ failure. 
Both the mortality and the development of extra-renal organ failure were similar between 
the early and the delayed group in both the AKIKI and the IDEAL ICU studies.  This does not 
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provide support for the hypothesis that RRT is harmful or indeed vice versa.  However what 
is of interest is that around 50% of patients in AKIKI and IDEAL-ICU received intermittent 
haemodialysis (IHD) as their modality of treatment whilst in the ICU, including many as a sole 
therapy which differs to contemporaneous practice across the rest of the world.  Moreover, 
approximately 45% of patients in the IDEAL-ICU study, all of whom had septic shock, 
receivied IHD as their initial treatment.  Concerns have long been raised regarding the risk of 
additional renal insult resulting from use of IHD in patients with AKI, potentially impairing 
recovery [3][4].  This is likely to be associated with the difficulty in controlling fluid balance 
with IHD without inducing intravascular hypovolaemia during a time-constrained period of 
ultrafiltration[5]. Controlling fluid balance over a short period of time (i.e. most often 4 to 6 
hours every 2 days) requires high ultrafiltration rates (UF) which induces hypovolemia and 
haemoconcentration.  This phenomenon is observed  in the treatment of chronic kidney 
disease (CKD) and is corrected during the hours following therapy through plasma refilling by 
the interstitial compartment [6][7]. Prescription of inappropriate high doses of UF rate will 
result in altered systemic hemodynamics[8], decrease cardiac output and induce intra-
dialytic hypotension particularly where the individual remains fluid responsive [9]. In a 
recent study intermittent hemodialysis was shown to decrease renal perfusion to 65% of 
baseline in about two thirds of patients with CKD [10]. The observed decrease in renal 
perfusion was associated with the intensity of UF (r=0.31, p=0.05 with mean UF). Such 
systemic hemodynamic alternations have long been shown to impair the chance of renal 
recovery after AKI [11] with more frequent exposure to haemodialysis conferring worse 
renal outcomes [12]. 
In AKIKI lower urine output after RRT initiation in the “early” vs restrictive group was 
reported, an observation interpreted by the authors as an exacerbation of renal injury. 
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Whether under these circumstances oliguria relates to adverse long term renal outcomes is 
unknown and importantly does this observation reveal an intrinsic side-effect of RRT or is it a 
consequence of applied modality.   Recently, a post-hoc analysis of the RENAL trial 
demonstrated that applying higher UF rates rate during CRRT (>1.75 ml/kg/hour) was 
associated with worse outcomes [13]. However, of note, the same authors have previously 
reported higher UF rates to manage fluid overload were associated with improved 
outcomes[14].  We believe that overall these observations are consistent with the known 
strong association between overall fluid balance and adverse outcomes in AKI and the 
acknowledged difficulty in resolving tissue fluid overload without inducing intravascular 
hypovolaemia.  Seen in this context earlier RRT with a continuous modality might be 
beneficial in limiting the extent of fluid accumulation, while late therapy, especially with IHD, 
might be harmful due to the requirement of higher UF rates to resolve accumulated fluid 
overload in the face of fixed vascular refilling (Figure). Therefore, we believe that the 
potential for harm arises where therapy is either given for the wrong indication or in an 
inappropriate fashion or indeed both.  By analogy with mechanical ventilation a tidal volume 
of 6ml/kg is less injurious than 12mkl/kg, however that does not mean that patients with 
severe respiratory failure do not benefit from some form of mechanical ventilation - just that 
we have to appreciate and minimize the intrinsic injurious nature. In using RRT, both the 
modality and UF rate are key factors in development of secondary renal injury. Ultrafiltration 
during RRT has the ability to “override” the circulation and therefore requires careful 
monitoring in order to reduce risk of harm. How to reach fluid balance targets needs better 
understanding of the monitoring and adjustment of UF rates [15].  
To conclude, we agree that AKI staging by serum creatinine and/or urine output are 
insufficient indications for commencing RRT, however RRT remains the key treatment of 
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both the metabolic and fluid overload consequences of severe AKI, in particular in the 
context of multi-organ dysfunction.   To provide safe and effective RRT we need to apply 
“kidney-protective” therapy as much as possible to limit any perceived harm.  In selected 
patients this may involve earlier implementation of a continuous RRT modality to limit fluid 
accumulation, while in other contexts watchful waiting may be appropriate. Differentiating 
these patient groups remains a key challenge in critical care nephrology. 
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Legend for Figure: Representation of fluid balance control using intermittent hemodialysis 
(IHD) or continuous renal replacement therapy (CRRT) in fluid overloaded patients in the 
intensive care unit (adapted from Alex Yartsev, www.derangedphysiology.com).  
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